Navigation Links
'We're Ready to Prove It!'
Date:12/27/2008

Brigitte Boisselier breaks 5-year silence, offers to ease cloning costs for Clonaid clients willing to go public

LAS VEGAS, Dec. 27 /PRNewswire-USNewswire/ -- Six years to the day after the birth of Baby Eve, the first cloned child, Dr. Brigitte Boisselier, head of the company that leads the Clonaid project, said Eve and other babies cloned by her company are growing up healthy and normal - and with no one invading their families' privacy.

"We've helped almost 100 families who were desperate to have a child," Boisselier said. "Our reward has been to see a number of cloned babies growing up normally, like any infant born through natural reproduction or through in vitro fertilization."

But she said the time has come to take things a step further.

"As of now, the Clonaid and Stemaid teams are ready to facilitate the cloning of one or more additional individuals at a reduced rate, provided they would agree - under contract - to go public after being cloned," Boisselier said. "We believe this is the right time to show publicly what we can do and offer the proof people wanted after the birth of Baby Eve."

She said many types of clients can benefit from her company's cloning technology.

"We can give hope to infertile and homosexual couples, to people who've lost a beloved family member and to single men and women who want a child created exclusively from their own genes," Boisselier said. "And we can also help those who suffer from ailments that can be cured with their own stem cells."

In addition, Boisselier announced the team's 500th clone blastocyst.

"Back in early 2002 when we had our first human clone blastocysts, we needed an average of 30 human eggs to get one good blastocyst," Boisselier explained. "Now, after seven years of practice, for every three eggs fused, we can repeatedly prepare one clone blastocyst. This is a milestone achievement."

Boisselier said 70 percent of the refined cloning technology developed by Clonaid scientists is now used for the preparation of embryonic stem cells made available through Clonaid's sister company, Stemaid (www.stemaid.com).

"I was tremendously moved by the happiness of those we've helped to have children through our cloning project," she said. "But I was probably even more touched when I saw a Stemaid patient who had had a stroke and then was treated with embryonic stem cells created through our cloning technology. After having several years of impaired speech, she was able to speak normally again."

Boisselier said that when her 2002 announcement of the first cloned baby was treated as a hoax after the parents decided not to go public, she chose to respect the privacy requests of other such parents as well.

"In doing so, I gained the trust of all future Clonaid patients as well as the necessary privacy to develop the technology further," she explained. "But we've come a long way since then. It's time to show the world the proof of what we're doing."

To learn more about Clonaid and Stemaid achievements, visit www.stemaid.com and www.clonaid.com or call 702-862-6495.


'/>"/>
SOURCE Clonaid
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Gene Therapy Provides Vision to People who Were Nearly Blind
2. Welchol(TM) Lowered A1C by a Mean 1 Percent or Greater When Added to Metformin-, Insulin-, or Sulfonylurea-Based Therapy in 47 Percent of Patients Evaluated
3. MTV and SpinVox Partner to Launch First Ever Integrated Voice Powered Cause-Related Social Networking Campaign Stand By What You Say
4. Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes
5. Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
6. JDSU WaveReady Receives Brocade Data Center Ready Status for Brocade-Based Storage Area Network (SAN) Infrastructures
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
9. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
10. Experimental Drug Ketasyn(TM) Improves Memory in Age-Associated Memory Impairment Study
11. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology company built ... Dr. Alfredo Zurlo as Chief Medical Officer. ... years clinical experience and a proven track record in ... at Mologen AG where he was Chief Medical Officer ... held various positions at F Hoffmann La Roche and ...
(Date:4/28/2016)... , April 28, 2016   Click ... Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... signed a definitive agreement to acquire Valley Campus ... Pharmacy ("TNH"), a leading specialty pharmacy that provides ... Nuys, California . In 2015, TNH generated ...
(Date:4/28/2016)... April 28, 2016 Research and ... Plastic Surgery Products Market 2016-2020" report to their ... , The global plastic surgery products market ... during the period 2016-2020. , ,The growing adoption of ... the growth of the market. Lasers are used to ...
Breaking Medicine Technology:
(Date:5/2/2016)... ... 2016 , ... Amica Life Insurance Company has unveiled ... various life stages. , The site launched on April 1, and it has ... to the times when life insurance matters most. , “Through our research, we ...
(Date:5/2/2016)... Washington, DC (PRWEB) , ... May 02, 2016 ... ... the Results and Data Book for the 2016 Main Residency Match® (“the Match”), ... residency positions in United States teaching institutions. A record-high 30,750 positions were placed ...
(Date:5/2/2016)... ... May 02, 2016 , ... Over $60 Billion is spent annually on ... and toys, leading product review site for Toys, Tots, Pets & More (TTPM) announced ... their Spring Showcase at the Metropolitan Pavilion in New York City. , Chosen from ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... This week ... for its 2016 guest season which runs through October. Omega is offering a record ... , “There has never been such widespread interest in or need for ...
(Date:5/2/2016)... ... ... Dr. Rassouli, dentist in Orange County, CA comments on the ... was published in the “Journal of the American Geriatrics Society,” more than a third ... Alzheimer’s disease. The study found that dental problems may increase the risk of heart ...
Breaking Medicine News(10 mins):